PerkinElmer receives CE Mark for SARS-CoV-2 assay

2020 09 30 21 25 9123 Perkin Elmer Headquarters 400

PerkinElmer has received a CE Mark for its SARS-CoV-2 real-time reverse transcription polymerase chain reaction (RT-PCR) assay. Now, saliva can be designated as a specimen type and there is an option to pool up to five specimens collected from individuals suspected of COVID-19 -- including asymptomatic individuals.

Saliva tests are less invasive, less risky, and reduce the need for frequent replacement of personal protective equipment (PPE) PerkinElmer said. The assay is built on the most sensitive SARS-CoV-2 test with the lowest limitation of detection in the market, according to the FDA's reference panel comparative data, the firm added.

Page 1 of 24
Next Page